These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 29217530

  • 1. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ, LCMC2 investigators.
    Clin Cancer Res; 2018 Mar 01; 24(5):1038-1047. PubMed ID: 29217530
    [Abstract] [Full Text] [Related]

  • 2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May 01; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A, Grosse C, Rechsteiner M, Soltermann A.
    Diagn Pathol; 2019 Feb 11; 14(1):18. PubMed ID: 30744664
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, Min YJ, Kim SW, Park K, Lee SS, Kim S, Kim HR, Cho BC, Korean Lung Cancer Consortium (KLCC).
    PLoS One; 2019 Feb 11; 14(11):e0224379. PubMed ID: 31765373
    [Abstract] [Full Text] [Related]

  • 9. Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
    Grosse C, Soltermann A, Rechsteiner M, Grosse A.
    PLoS One; 2019 Feb 11; 14(8):e0220691. PubMed ID: 31386689
    [Abstract] [Full Text] [Related]

  • 10. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y, Dong Y, Zhao R, Zhang B, Wang S, Zhang L, Hu M, He Q, Zhang W, Han B.
    Clin Lung Cancer; 2020 Sep 11; 21(5):e355-e362. PubMed ID: 32139332
    [Abstract] [Full Text] [Related]

  • 11. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 12. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
    El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, Benmokhtar S, Lamrani Alaoui H, El Annaz H, Abi R, Tagajdid MR, El Kochri S, El Mchichi B, Bouaiti EA, Lahlou IA, El Hassani RA, Ennibi K.
    Technol Cancer Res Treat; 2024 Apr 26; 23():15330338241288907. PubMed ID: 39363851
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
    Nagahashi M, Sato S, Yuza K, Shimada Y, Ichikawa H, Watanabe S, Takada K, Okamoto T, Okuda S, Lyle S, Takabe K, Tsuchida M, Wakai T.
    J Surg Res; 2018 Oct 26; 230():181-185. PubMed ID: 30072189
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers.
    Tessema M, Rossi MR, Picchi MA, Yingling CM, Lin Y, Ramalingam SS, Belinsky SA.
    Lung Cancer; 2018 Sep 26; 123():99-106. PubMed ID: 30089603
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.
    Oncologist; 2016 Jun 26; 21(6):684-91. PubMed ID: 27151654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.